Prognostic and predictive factors in the targeted therapy era: filling in the blanks.
Jonasch
Eric
E
GU Medical Oncology, The University of Texas, Anderson Cancer Center, Department of Genitourinary Medical Oncology, Unit 1374, PO Box 301439, Houston, TX 77230-1439, USA. ejonasch@mdanderson.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A